605116 奥锐特
已收盘 11-13 15:00:00
资讯
新帖
简况
奥锐特（605116）11月9日主力资金净卖出29.00万元
证券之星 · 11-09
奥锐特（605116）11月9日主力资金净卖出29.00万元
奥锐特（605116）11月2日主力资金净卖出588.64万元
证券之星 · 11-02
奥锐特（605116）11月2日主力资金净卖出588.64万元
奥锐特（605116）2026年三季报简析：净利润同比下降37.53%
证券之星 · 11-01
奥锐特（605116）2026年三季报简析：净利润同比下降37.53%
奥锐特(605116.SH)发布前三季度业绩，归母净利润2.21亿元，同比下降37.53%
智通财经 · 10-30
奥锐特(605116.SH)发布前三季度业绩，归母净利润2.21亿元，同比下降37.53%
奥锐特(605116)9月30日股东户数1.41万户，较上期增加4.56%
证券之星 · 10-30
奥锐特(605116)9月30日股东户数1.41万户，较上期增加4.56%
股市必读：奥锐特新发布《奥锐特药业股份有限公司关于可转债转股结果暨股份变动公告》
证券之星 · 10-12
股市必读：奥锐特新发布《奥锐特药业股份有限公司关于可转债转股结果暨股份变动公告》
股市必读：奥锐特新发布《奥锐特药业股份有限公司关于可转债转股结果暨股份变动公告》
证券之星 · 10-09
股市必读：奥锐特新发布《奥锐特药业股份有限公司关于可转债转股结果暨股份变动公告》
奥锐特（605116）9月29日主力资金净卖出82.20万元
证券之星 · 09-29
奥锐特（605116）9月29日主力资金净卖出82.20万元
研报掘金丨浙商证券：维持奥锐特“增持”评级，TIDES业务蓄势待发
格隆汇 · 09-08
研报掘金丨浙商证券：维持奥锐特“增持”评级，TIDES业务蓄势待发
奥锐特（605116）披露2026年半年度报告，8月31日股价下跌1.92%
证券之星 · 08-31
奥锐特（605116）披露2026年半年度报告，8月31日股价下跌1.92%
每周股票复盘：奥锐特（605116）股东户数降14.46%，净利降32.42%
证券之星 · 08-30
每周股票复盘：奥锐特（605116）股东户数降14.46%，净利降32.42%
图解奥锐特中报：第二季度单季净利润同比下降17.89%
证券之星 · 08-28
图解奥锐特中报：第二季度单季净利润同比下降17.89%
奥锐特（605116）披露全资子公司获得药品补充申请批准通知书，8月25日股价上涨2.57%
证券之星 · 08-25
奥锐特（605116）披露全资子公司获得药品补充申请批准通知书，8月25日股价上涨2.57%
每周股票复盘：奥锐特（605116）子公司通过美国FDA现场检查
证券之星 · 08-16
每周股票复盘：奥锐特（605116）子公司通过美国FDA现场检查
股市必读：奥锐特新发布《奥锐特药业股份有限公司关于全资子公司通过美国FDA现场检查的公告》
证券之星 · 08-14
股市必读：奥锐特新发布《奥锐特药业股份有限公司关于全资子公司通过美国FDA现场检查的公告》
全球首家！奥锐特药业通过美国FDA现场检查，开创寡核苷酸仿制药制造先河
美股速递 · 08-13
全球首家！奥锐特药业通过美国FDA现场检查，开创寡核苷酸仿制药制造先河
奥锐特（605116）披露全资子公司通过美国FDA现场检查公告，8月12日股价上涨0.83%
证券之星 · 08-12
奥锐特（605116）披露全资子公司通过美国FDA现场检查公告，8月12日股价上涨0.83%
奥锐特(605116.SH)子公司通过美国FDA现场检查
智通财经 · 08-12
奥锐特(605116.SH)子公司通过美国FDA现场检查
每周股票复盘：奥锐特（605116）两产品拟中选集采
证券之星 · 08-09
每周股票复盘：奥锐特（605116）两产品拟中选集采
股市必读：奥锐特新发布《奥锐特药业股份有限公司关于公司产品拟中选第十二批全国药品集中采购的公告》
证券之星 · 08-04
股市必读：奥锐特新发布《奥锐特药业股份有限公司关于公司产品拟中选第十二批全国药品集中采购的公告》
加载更多
公司概况
公司名称：
奥锐特药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-09-21
主营业务：
奥锐特药业股份有限公司的主营业务是特色复杂原料药、医药中间体和制剂的研发、生产和销售。公司的主要产品是地屈孕酮片奥欣桐、雌二醇片/雌二醇地屈孕酮片复合包装奥舒桐、恩扎卢胺君必坦、多替拉韦钠奥欣凯、小分子药物、多肽药物、寡核苷酸药物。
发行价格：
8.37
{"stockData":{"symbol":"605116","market":"SH","secType":"STK","nameCN":"奥锐特","latestPrice":17.78,"timestamp":1794553200000,"preClose":18,"halted":0,"volume":1952700,"delay":0,"changeRate":-0.0122,"floatShares":405999999,"shares":405999999,"eps":0.7793,"marketStatus":"已收盘","change":-0.22,"latestTime":"11-13 15:00:00","open":18,"high":18.02,"low":17.59,"amount":34649100,"amplitude":0.0239,"askPrice":17.8,"askSize":24,"bidPrice":17.78,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.7793,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":5,"adr":0,"adjPreClose":18,"symbolType":"stock","openAndCloseTimeList":[[1794533400000,1794540600000],[1794546000000,1794553200000]],"highLimit":19.8,"lowLimit":16.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":406183234,"isCdr":false,"pbRate":2.66,"roa":"--","peRate":22.815347,"roe":"8.11%","epsLYR":1.12,"committee":-0.137931,"marketValue":7222000000,"turnoverRate":0.0048,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-16。","floatMarketCap":7222000000},"requestUrl":"/m/hq/s/605116","defaultTab":"news","newsList":[{"id":"2682779728","title":"奥锐特（605116）11月9日主力资金净卖出29.00万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682779728","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682779728?lang=zh_cn&edition=full","pubTime":"2026-11-09 15:31","pubTimestamp":1794209477,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月9日收盘，奥锐特报收于18.09元，下跌2.74%，换手率0.43%，成交量1.74万手，成交额3184.44万元。11月9日的资金流向数据方面，主力资金净流出29.0万元，占总成交额0.91%，游资资金净流入159.1万元，占总成交额5.0%，散户资金净流出130.1万元，占总成交额4.09%。奥锐特主营业务：特色复杂原料药、医药中间体和制剂的研发、生产和销售。该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900009425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680173987","title":"奥锐特（605116）11月2日主力资金净卖出588.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680173987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680173987?lang=zh_cn&edition=full","pubTime":"2026-11-02 15:28","pubTimestamp":1793604504,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月2日收盘，奥锐特报收于17.46元，下跌4.38%，换手率0.97%，成交量3.95万手，成交额6861.35万元。11月2日的资金流向数据方面，主力资金净流出588.64万元，占总成交额8.58%，游资资金净流入45.91万元，占总成交额0.67%，散户资金净流入542.73万元，占总成交额7.91%。奥锐特主营业务：特色复杂原料药、医药中间体和制剂的研发、生产和销售。该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200017265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680272813","title":"奥锐特（605116）2026年三季报简析：净利润同比下降37.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680272813","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680272813?lang=zh_cn&edition=full","pubTime":"2026-11-01 06:22","pubTimestamp":1793485366,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期奥锐特发布2026年三季报。根据财报显示，奥锐特净利润同比下降37.53%。截至本报告期末，公司营业总收入12.14亿元，同比下降1.87%，归母净利润2.21亿元，同比下降37.53%。按单季度数据看，第三季度营业总收入3.86亿元，同比下降7.1%，第三季度归母净利润6211.23万元，同比下降47.65%。本文数据来源于奥锐特2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110100001308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679524591","title":"奥锐特(605116.SH)发布前三季度业绩，归母净利润2.21亿元，同比下降37.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679524591","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679524591?lang=zh_cn&edition=full","pubTime":"2026-10-30 23:37","pubTimestamp":1793374640,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥锐特(605116.SH)发布2026年三季度报告，前三季度，公司实现营业收入12.14亿元，同比下降1.87%。归属于上市公司股东的净利润2.21亿元，同比下降37.53%。归属于上市公司股东的扣除非经常性损益的净利润2.15亿元，同比下降37.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679218151","title":"奥锐特(605116)9月30日股东户数1.41万户，较上期增加4.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679218151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679218151?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:09","pubTimestamp":1793358561,"startTime":"0","endTime":"0","summary":"证券之星消息，近日奥锐特披露，截至2026年9月30日公司股东户数为1.41万户，较6月30日增加615.0户，增幅为4.56%。在化学制药行业个股中，奥锐特股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.98万户。从股价来看，2026年6月30日至2026年9月30日，奥锐特区间涨幅为6.08%，在此期间股东户数增加615.0户，增幅为4.56%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674849134","title":"股市必读：奥锐特新发布《奥锐特药业股份有限公司关于可转债转股结果暨股份变动公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674849134","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674849134?lang=zh_cn&edition=full","pubTime":"2026-10-12 05:14","pubTimestamp":1791753259,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，奥锐特报收于20.02元，上涨0.91%，换手率0.68%，成交量2.76万手，成交额5488.36万元。公司公告汇总奥锐特药业股份有限公司关于可转债转股结果暨股份变动公告截至2026年9月30日，累计已有面值34,000元“奥锐转债”转为公司A股普通股，累计转股股数为1,353股，占开始转股前总股本的0.0003%。2026年7月1日至9月30日期间无转股。尚未转股的可转债面值为812,086,000元，占发行总量的99.9958%。本期股本无变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200001700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674700281","title":"股市必读：奥锐特新发布《奥锐特药业股份有限公司关于可转债转股结果暨股份变动公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674700281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674700281?lang=zh_cn&edition=full","pubTime":"2026-10-09 02:26","pubTimestamp":1791483972,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月8日主力资金净流出335.75万元，占总成交额6.7%； 公司公告汇总：截至2026年9月30日，“奥锐转债”累计转股1,353股，占开始转股前总股本的0.0003%，本期股本无变动。公司公告汇总奥锐特药业股份有限公司关于可转债转股结果暨股份变动公告截至2026年9月30日，累计已有面值34,000元“奥锐转债”转为公司A股普通股，累计转股股数为1,353股，占开始转股前总股本的0.0003%。2026年7月1日至9月30日期间无转股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900002281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671429136","title":"奥锐特（605116）9月29日主力资金净卖出82.20万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671429136","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671429136?lang=zh_cn&edition=full","pubTime":"2026-09-29 15:27","pubTimestamp":1790666849,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月29日收盘，奥锐特报收于19.28元，下跌1.38%，换手率0.35%，成交量1.4万手，成交额2720.79万元。9月29日的资金流向数据方面，主力资金净流出82.2万元，占总成交额3.02%，游资资金净流入151.72万元，占总成交额5.58%，散户资金净流出69.52万元，占总成交额2.56%。奥锐特主营业务：特色复杂原料药、医药中间体和制剂的研发、生产和销售。该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900020186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665944347","title":"研报掘金丨浙商证券：维持奥锐特“增持”评级，TIDES业务蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2665944347","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665944347?lang=zh_cn&edition=full","pubTime":"2026-09-08 14:19","pubTimestamp":1788848351,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["605116","601878","BK0276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663541072","title":"奥锐特（605116）披露2026年半年度报告，8月31日股价下跌1.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663541072","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663541072?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:35","pubTimestamp":1788172510,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，奥锐特报收于19.88元，较前一交易日下跌1.92%，最新总市值为80.75亿元。该股当日开盘20.1元，最高20.18元，最低19.8元，成交额达4909.41万元，换手率为0.61%。近日，奥锐特药业股份有限公司披露《2026年半年度报告》。公告显示，截至报告期末，公司总资产为4,170,990,974.20元，较上年度末减少1.21%；归属于上市公司股东的净资产为2,675,858,910.14元，较上年度末增长0.69%。经营活动产生的现金流量净额为207,754,780.38元，同比减少3.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100029315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663612043","title":"每周股票复盘：奥锐特（605116）股东户数降14.46%，净利降32.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663612043","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663612043?lang=zh_cn&edition=full","pubTime":"2026-08-30 07:30","pubTimestamp":1788046240,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，奥锐特报收于20.27元，较上周的19.95元上涨1.6%。股本股东变化股东户数变动截至2026年6月30日，奥锐特股东户数为1.35万户，较3月31日减少2282.0户，减幅14.46%。业绩披露要点财务报告奥锐特2026年中报显示，上半年主营收入8.28亿元，同比上升0.78%；归母净利润1.59亿元，同比下降32.42%；扣非净利润1.53亿元，同比下降32.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000003896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662306064","title":"图解奥锐特中报：第二季度单季净利润同比下降17.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662306064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662306064?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:35","pubTimestamp":1787913350,"startTime":"0","endTime":"0","summary":"证券之星消息，奥锐特2026年中报显示，上半年度公司主营收入8.28亿元，同比上升0.78%；归母净利润1.59亿元，同比下降32.42%；扣非净利润1.53亿元，同比下降32.43%；其中2026年第二季度，公司单季度主营收入4.39亿元，同比上升4.56%；单季度归母净利润9481.66万元，同比下降17.89%；单季度扣非净利润9433.54万元，同比下降16.75%；负债率35.85%，投资收益534.21万元，财务费用4418.52万元，毛利率54.85%。财报数据概要请见下图:本文数据来源于奥锐特2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800043598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662736253","title":"奥锐特（605116）披露全资子公司获得药品补充申请批准通知书，8月25日股价上涨2.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736253","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662736253?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:57","pubTimestamp":1787655460,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，奥锐特报收于19.98元，较前一交易日上涨2.57%，最新总市值为81.16亿元。奥锐特药业股份有限公司于近日披露《关于全资子公司获得药品补充申请批准通知书的公告》。公告显示，公司全资子公司扬州奥锐特药业有限公司收到国家药监局核准签发的雌二醇片/雌二醇地屈孕酮片复合包装《药品补充申请批准通知书》，批准增加规格，并核发药品批准文号。截至目前，国内已有2家企业通过一致性评价，分别为雅培和扬州奥锐特。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500040169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162176","title":"每周股票复盘：奥锐特（605116）子公司通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162176","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659162176?lang=zh_cn&edition=full","pubTime":"2026-08-16 03:20","pubTimestamp":1786821623,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，奥锐特报收于20.83元，较上周的20.55元上涨1.36%。本周关注点公司公告汇总：全资子公司扬州奥锐特药业有限公司通过美国FDA的cGMP现场检查，质量管理体系获认可。公司公告汇总奥锐特药业股份有限公司全资子公司扬州奥锐特药业有限公司于2026年6月15日至19日接受美国FDA的cGMP现场检查，检查范围涵盖英克司兰钠、司美格鲁肽、柯拉特龙、布立西坦等品种，涉及批准前检查及已上市产品常规GMP合规性检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659016155","title":"股市必读：奥锐特新发布《奥锐特药业股份有限公司关于全资子公司通过美国FDA现场检查的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659016155","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659016155?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:55","pubTimestamp":1786643716,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，奥锐特报收于21.17元，上涨2.27%，换手率1.86%，成交量7.57万手，成交额1.62亿元。当日关注点交易信息汇总：8月13日主力资金净流出339.18万元，占总成交额2.1%。公司公告汇总：全资子公司扬州奥锐特药业有限公司于2026年6月15日至19日通过美国FDA cGMP现场检查，涉及英克司兰钠、司美格鲁肽等多品种，确认质量管理体系符合FDA标准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132588002","title":"全球首家！奥锐特药业通过美国FDA现场检查，开创寡核苷酸仿制药制造先河","url":"https://stock-news.laohu8.com/highlight/detail?id=1132588002","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132588002?lang=zh_cn&edition=full","pubTime":"2026-08-13 03:01","pubTimestamp":1786561270,"startTime":"0","endTime":"0","summary":"奥锐特药业（Aurisco Pharmaceutical）近日宣布，该公司已成功通过美国食品药品监督管理局的现场检查，从而成为全球首家获得这一认证的寡核苷酸仿制药制造商。这一里程碑式的成就，不仅彰显了奥锐特在生产工艺、质量控制与合规管理上的卓越水准，更标志着中国制药企业在高端仿制药领域取得了突破性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","605116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658054903","title":"奥锐特（605116）披露全资子公司通过美国FDA现场检查公告，8月12日股价上涨0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658054903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658054903?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:22","pubTimestamp":1786544540,"startTime":"0","endTime":"0","summary":"近日，奥锐特药业股份有限公司发布《关于全资子公司通过美国FDA现场检查的公告》。公告显示，公司全资子公司扬州奥锐特药业有限公司于2026年6月15日至19日接受美国FDA的cGMP现场检查，检查范围包括英克司兰钠、司美格鲁肽、柯拉特龙、布立西坦等品种，涉及批准前检查及已上市产品常规GMP合规性检查。公司收到FDA通知函及现场检查报告，确认质量管理体系符合FDA标准，顺利通过检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658783029","title":"奥锐特(605116.SH)子公司通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2658783029","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658783029?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:47","pubTimestamp":1786524460,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥锐特(605116.SH)发布公告，公司全资子公司扬州奥锐特药业有限公司(简称“扬州奥锐特”)于2026年06月15日-19日接受了来自美国食品药品监督管理局(FDA)的cGMP(现行药品生产质量管理规范)现场检查。近日，扬州奥锐特收到美国FDA的通知函和针对本次检查签发的现场检查报告。该通知说明扬州奥锐特的质量管理体系符合美国FDA的标准，顺利通过了美国FDA的批准前检查以及已上市产品的常规GMP合规性检查。检查范围包括英克司兰钠、司美格鲁肽、柯拉特龙、布立西坦等产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4585","BK4588","605116","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658675566","title":"每周股票复盘：奥锐特（605116）两产品拟中选集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2658675566","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658675566?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:42","pubTimestamp":1786214533,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，奥锐特报收于20.55元，较上周的19.52元上涨5.28%。本周，奥锐特8月4日盘中最高价报20.69元。奥锐特当前最新总市值83.47亿元，在化学制药板块市值排名64/149，在两市A股市值排名2114/5205。本周关注点公司公告汇总：奥锐特恩扎卢胺片和地屈孕酮片拟中选第十二批全国药品集中采购。本次集采采购周期至2029年12月31日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656305538","title":"股市必读：奥锐特新发布《奥锐特药业股份有限公司关于公司产品拟中选第十二批全国药品集中采购的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656305538","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656305538?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:32","pubTimestamp":1785778332,"startTime":"0","endTime":"0","summary":"公司公告汇总奥锐特药业股份有限公司关于公司产品拟中选第十二批全国药品集中采购的公告2026年7月31日，奥锐特药业股份有限公司参加第十二批全国药品集中采购投标，公司恩扎卢胺片和地屈孕酮片拟中选。恩扎卢胺片于2026年3月获批，尚未实现销售；地屈孕酮片于2023年6月获批，2025年国内销售额约18,433.49万元，占公司当年营业收入的10.86%。本次采购周期至2029年12月31日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794683495104,"stockEarnings":[{"period":"1week","weight":-0.0441},{"period":"1month","weight":-0.0706},{"period":"3month","weight":-0.1464},{"period":"6month","weight":-0.1595},{"period":"1year","weight":-0.2253},{"period":"ytd","weight":-0.2782}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0746},{"period":"6month","weight":-0.1212},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"奥锐特药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14112人(较上一季度增加4.56%)","perCapita":"28782股","listingDate":"2020-09-21","address":"浙江省台州市天台县八都工业园区","registeredCapital":"40618万元","survey":" 奥锐特药业股份有限公司的主营业务是特色复杂原料药、医药中间体和制剂的研发、生产和销售。公司的主要产品是地屈孕酮片奥欣桐、雌二醇片/雌二醇地屈孕酮片复合包装奥舒桐、恩扎卢胺君必坦、多替拉韦钠奥欣凯、小分子药物、多肽药物、寡核苷酸药物。","listedPrice":8.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥锐特(605116)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥锐特(605116)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥锐特,605116,奥锐特股票,奥锐特股票老虎,奥锐特股票老虎国际,奥锐特行情,奥锐特股票行情,奥锐特股价,奥锐特股市,奥锐特股票价格,奥锐特股票交易,奥锐特股票购买,奥锐特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥锐特(605116)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥锐特(605116)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}